How do you envision incorporating CAR-T therapy into your clinical rheumatology practice?

This is an excellent question—one that, for now, might best be explored over a glass of white wine and some lively hand-waving. It’s a question I often find myself reflecting on every time I hear a presentation or read a new paper on the subject. Here’s a brief editorial response outlining how I env...

I agree with Dr. @Dr. First Last who gives a nice detailed answer. I'm very impressed with this technology. Over 43 patients with severe SLE have been treated with CAR-T and reported in the literature. Almost all went into a prolonged drug-free remission The 1st two from China post-BCMA/CD-19 CAR-T ...

I envision incorporating CAR-T therapy into clinical rheumatology by first identifying the right patient. At present, this would mean carefully selected patients with severe, refractory, or progressive autoimmune disease despite appropriate standard therapies, particularly those with organ-threateni...

I view CAR-T therapy much the way rheumatologists viewed infliximab (Remicade) in the late 1990s: not as the end of the story, but as the beginning of a new therapeutic era.

When Remicade was introduced, it transformed our ability to treat autoimmune disease. Yet its greatest contribution may have b...